Skip to main content
. 2014 Jun 10;142(3):354–362. doi: 10.1111/imm.12212

Figure 4.

Figure 4

CD8+ CD45RO+/RA+ ratio at baseline and after each rituximab cycle. (a) After gating on CD8+ lymphocytes, the expression of CD45RO+ or CD45RA+ was analysed in patients segregated according to serum interleukin-15 (IL-15) levels: serIL-15+ (baseline and I cycle n = 25, II-cycle n = 17 and III-cycle n = 13) and serIL-15− (baseline and I-cycle n = 8, II-cycle n = 6 and III-cycle n = 4) patients. Results were expressed as the mean and error bars represent SD. P-values correspond to the comparison of the ratio after third cycle of treatment with the baseline (t = 0) by Wilcoxon test for paired samples. (b) Correlation between log-transformed CD8+ CD45RO+/RA+ ratio and DAS28 (n = 33).